Company Overview and News

 
Elite's hypocrisy, bullying, culture of greed exposed

2018-10-14 smh.com.au
Elizabeth Farrelly brilliantly exposes the hypocrisy of those who excuse the bullying of Alan Jones, a man who had not one, but two horses in the Everest race ("The big lie about Sydney's true elite", Oct 13-14) .
PARRO

28
Is Kratos Defense & Security Solutions, Inc Stock a Bargain or a Big Trap?

2018-04-20 investorplace
Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS) had been having a pretty unremarkable 2018. Investors were optimistic that Trump’s policies would lead to more defense spending and contracts. But operational results weren’t strong enough to make KTOS stock move that much, and it largely traded in a range.
PARRO KTOS AVAV

3
Spruce Issues Strong Sell Opinion On Kratos Defense & Security Solutions, Inc (KTOS), Sees 40% - 70% Downside Risk

2018-03-17 valuewalk
Spruce Point Capital Management is pleased to announce it has released the contents of a unique research report on Kratos Defense & Security Solutions, Inc. (Nasdsq: KTOS) (“Kratos” or “the Company”).
LMT PARRO

50
A Critical Forensic Look At Kratos Defense & Security Solutions Makes The Case For 40% To 70% Downside

2018-03-16 seekingalpha - 8
Kratos' remarkable turnaround from the brink of default in 2015, and promotion of its drone business merits scrutiny.
LMT GD PARRO KTOS CFO AVAV CIO CEO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:PARRO / PARROT on message board site Silicon Investor.

Barronu0027s Sparrows!!!! Barronu0027s Sparrows!!!! Barronu0027s Sparrows!!!! Adelphia Communications: Crumbs for the Equity Sparrows? Adelphia Communications: Crumbs for the Equity Sparrows? Adelphia Communications: Crumbs for the Equity Sparrows?
Polly the Parrot- Queen of test threads Polly the Parrot- Queen of test threads Polly the Parrot- Queen of test threads SAILORS, BOATERS AND PARROTHEADS UNITE!!! SAILORS, BOATERS AND PARROTHEADS UNITE!!! SAILORS, BOATERS AND PARROTHEADS UNITE!!!